The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Oral capecitabine or tegafur/gimeracil/oteracil as induction and adjuvant/maintenance chemotherapy in the management of stage III-IVb nasopharyngeal carcinoma: A systematic-review and meta-analysis.
 
Edgar Theodore Polintan
No Relationships to Disclose
 
Yuhe Guo
No Relationships to Disclose
 
Lucia Ramirez-Garcia
No Relationships to Disclose
 
Kevin Bryan Lo
No Relationships to Disclose
 
Sandeep Samethadka Nayak
No Relationships to Disclose
 
Herbert H. F. Loong
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Eisai; GlaxoSmithKline; Guardant Health; Illumina; Lilly; Novartis; Roche/Genentech; Takeda
Speakers' Bureau - Bayer; Guardant Health; Ignyta; Novartis
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Pfizer; Roche
 
Miguel Angel Villalona-Calero
Stock and Other Ownership Interests - Moderna Therapeutics
Consulting or Advisory Role - Lilly
Speakers' Bureau - Amgen
Research Funding - Altor BioScience (Inst); Bristol-Myers Squibb (Inst); Guardant Health (Inst); Merck (Inst); Novocure (Inst); Tolero Pharmaceuticals (Inst)